LYEL

13.55

2.87% -0.40

Handel nachbörslich: 13.55

Lyell Immunopharma Inc (LYEL)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$13.95

Offen:

$13.86

24-Stunden-Volumen:

132.52K

Relative Volume:

0.76

Marktkapitalisierung:

$332.04M

Einnahmen:

$31,000

Nettoeinkommen (Verlust:

$-246.41M

KGV:

-1.0638

EPS:

-12.7377

Netto-Cashflow:

$-134.42M

1W Leistung:

-5.44%

1M Leistung:

+1.73%

6M Leistung:

-46.61%

1J Leistung:

+28.07%

1-Tages-Spanne:

$13.39

$13.93

1-Wochen-Bereich:

$13.39

$15.52

52-Wochen-Spanne:

$10.49

$45.00

Lyell Immunopharma Inc Stock (LYEL) Company Profile

Firmenname

Lyell Immunopharma Inc

Sektor

Healthcare (1082)

Branche

Biotechnology (606)

Telefon

650 695-0677

Adresse

201 HASKINS WAY, SOUTH SAN FRANCISCO

Mitarbeiter

161

Twitter

Nächster Verdiensttermin

2026-08-11

Neueste SEC-Einreichungen

LYEL's Discussions on Twitter

Compare LYEL vs VRTX, REGN, ARGX, RVMD, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
LYEL Lyell Immunopharma Inc	13.55	341.85M	31,000	-246.41M	-134.42M	-12.74
VRTX Vertex Pharmaceuticals Inc	515.55	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.93	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	987.84	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	212.00	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.51	39.31B	5.76B	514.49M	1.10B	4.4813

Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-10	Eingeleitet	Needham	Buy
2026-03-09	Eingeleitet	Citizens	Mkt Outperform
2025-12-09	Hochstufung	H.C. Wainwright	Neutral → Buy
2024-10-30	Herabstufung	BofA Securities	Buy → Underperform
2024-06-27	Herabstufung	H.C. Wainwright	Buy → Neutral
2023-08-28	Herabstufung	JP Morgan	Overweight → Neutral
2022-11-14	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-11-11	Herabstufung	Goldman	Buy → Neutral
2022-10-17	Eingeleitet	H.C. Wainwright	Buy
2021-07-12	Eingeleitet	BofA Securities	Buy
2021-07-12	Eingeleitet	Goldman	Buy
2021-07-12	Eingeleitet	JP Morgan	Overweight
2021-07-12	Eingeleitet	Morgan Stanley	Overweight

Alle ansehen

Lyell Immunopharma Inc Aktie (LYEL) Neueste Nachrichten

Aug 14, 2026

Lyell Immunopharma (LYEL): Foresite funds and Tananbaum report 2.7% ownership - Stock Titan

Aug 14, 2026

Citizens reiterates Lyell Immunopharma stock rating on pipeline progress By Investing.com - Investing.com Canada

Aug 14, 2026

Aug 13, 2026

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Given Average Recommendation of "Moderate Buy" by Brokerages - marketbeat.com

Aug 13, 2026

Aug 12, 2026

Lyell Immunopharma (LYEL) Slides 4.77% to $14.17 as Biotech Risk Appetite FadesTriple Top - dars.gov.et

Aug 12, 2026

Aug 11, 2026

Lyell Immunopharma VP Bulis sells $8,905 of common stock By Investing.com - Investing.com Nigeria

Aug 11, 2026

Lyell Immunopharma VP Veronica Sanchez Bulis Sells 621 Shares for Tax Withholding on August 10, 2026 - Kalkine Media

Aug 11, 2026

Lyell Immunopharma COO Stephen J. Hill Sells Shares to Cover Tax Withholding on RSU Settlement - Kalkine Media

Aug 11, 2026

Lyell Immunopharma (LYEL) CSO auto-sells shares to cover RSU tax withholding - Stock Titan

Aug 11, 2026

Lyell Immunopharma VP Bulis sells $8,905 of common stock - Investing.com

Aug 11, 2026

Lyell Immunopharma (LYEL) VP auto-sells 621 shares to cover RSU taxes - Stock Titan

Aug 11, 2026

Lyell Immunopharma (LYEL) COO auto-sells 89 shares for RSU tax withholding - Stock Titan

Aug 11, 2026

Lyell Immunopharma (LYEL) CEO sells shares to cover RSU tax withholding - Stock Titan

Aug 11, 2026

Renaissance Technologies LLC Buys 76,921 Shares of Lyell Immunopharma, Inc. $LYEL - marketbeat.com

Aug 11, 2026

Aug 10, 2026

Lyell Immunopharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 10, 2026

Aug 09, 2026

Lyell Immunopharma earnings beat by $0.22, revenue fell short of estimates - Investing.com Canada

Aug 09, 2026

Aug 08, 2026

Possible Signal As Lyell Immunopharma Insiders Sell US$527k In Stock - webull.com

Aug 08, 2026

Lyell Immunopharma (NASDAQ:LYEL) Posts Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat

Aug 08, 2026

Aug 07, 2026

Lyell Immunopharma, Inc. expected to post a loss of $2.08 a shareEarnings Preview - TradingView

Aug 07, 2026

Aug 06, 2026

Lyell Immunopharma: Q2 Earnings Snapshot - AOL.com

Aug 06, 2026

Lyell Immunopharma reports Q2 2026 net loss $44.8M, cash $228.0M; clinical milestones advance - TradingView

Aug 06, 2026

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 - manilatimes.net

Aug 06, 2026

BRIEF-Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million - TradingView

Aug 06, 2026

This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga

Aug 06, 2026

Lyell Immunopharma (NASDAQ:LYEL) Earns Buy Rating from Analysts at Stifel Nicolaus - MarketBeat

Aug 06, 2026

Stifel Initiates Lyell Immunopharma(LYEL.US) With Buy Rating, Announces Target Price $36 - Moomoo

Aug 06, 2026

Aug 05, 2026

LYELL IMMUNOPHARMA, INC. : STIFEL INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $36 - Bitget

Aug 05, 2026

Stifel initiates Lyell Immunopharma stock with buy rating on CAR T therapy - Investing.com South Africa

Aug 05, 2026

LYEL Q2'26 Earnings: revenue estimate is 4.60K USD - TradingView

Aug 05, 2026

Aug 04, 2026

Lyell Immunopharma (LYEL) Projected to Post Quarterly Earnings on Tuesday - MarketBeat

Aug 04, 2026

Jul 29, 2026

Price to book forward of Lyell Immunopharma, Inc. – NASDAQ:LYEL - TradingView

Jul 29, 2026

Jul 27, 2026

Form 4 Lyell Immunopharma Inc For: 27 July By Investing.com - Investing.com Nigeria

Jul 27, 2026